Cipla is looking to acquire around 25 per cent in the manufacturing division of Cipla Medpro, where it does not hold any stake at present. The deal size could not be ascertained, but it will be the first overseas acquisition by 75-year-old Cipla in any pharmaceutical company. Cipla Medpro, is setting up one of the largest contract manufacturing facilities in Africa at an investment of over Rand 225 million (Rs 145 crore.Recently, it acquired a 25 per cent stake in a Hong Kong-based biotech company with manufacturing units in
Cipla Medpro has three business segments in pharmaceuticals: manufacturing, animal health and agricare. It had a turnover of around Rs 811 crore in 2009. It markets and manufactures drugs in cardio-respiratory, diabetes, oncology, psychiatry and HIV-AIDS categories. It is also the only local company to offer a full basket of diabetes products, such as insulin, oral medications, over-the-counter and Diagnostics.The Company has been a strategic business partner of Cipla for the last 18 years.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1642.80 |
| Dr. Reddys Lab | 1206.10 |
| Cipla | 1205.40 |
| Zydus Lifesciences | 904.70 |
| Lupin | 2310.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: